Plain-English translation of NCT05407636 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing ABBV-RGX-314, a new gene therapy designed to treat wet age-related macular degeneration (a serious eye condition that affects vision). In the study, some participants will receive this medication through a surgical injection into the eye, while others will receive standard injections of a medicine called aflibercept. The goal is to see whether the medication can help slow vision loss or even improve vision better than current treatments.
Current treatments for wet age-related macular degeneration require regular injections into the eye every 6–8 weeks for years. This new medication is being tested because it's designed to work from a single treatment, potentially reducing the burden of frequent injections while maintaining or improving the benefit to your vision.
If you join this study, you'll be randomly assigned to one of three groups: two groups receiving the new gene therapy through a single surgical procedure, or a control group receiving standard aflibercept injections roughly every 8 weeks. You'll visit the clinic regularly so doctors can monitor your vision and eye health over the course of the study. The main study lasts about a year, and some participants with vision problems in both eyes may be invited to participate in an additional substudy lasting at least 50 weeks.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
United States